<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">While there have been no randomized, controlled clinical trials of antivirals against MERS-CoV, ribavirin and mycophenolate mofetil (an immunosuppressive agent used commonly in transplantation) have in vitro activity against the virus [
 <xref ref-type="bibr" rid="CR43">43</xref>]. Ribavirin (in combination with interferon α-2b) has demonstrated promise in decreasing lung injury and viral replication in rhesus macaques infected with MERS-CoV [
 <xref ref-type="bibr" rid="CR44">44</xref>]. A retrospective cohort study describing the use of ribavirin and interferon α-2a in twenty patients with severe infection demonstrated an early survival benefit [
 <xref ref-type="bibr" rid="CR45">45</xref>].
</p>
